Connect Biopharma Holdings Limited — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone 2022 Q4 report; the filing does not provide clear standalone fourth-quarter financial results. Financial statements are prepared under IFRS and reported in RMB, with USD translations for convenience.
Business context and key financial metrics
Connect Biopharma is a clinical-stage biopharmaceutical company developing treatments for T-cell-driven inflammatory diseases. It had no approved products and generated no revenue in 2022 or 2021.
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | RMB 652.2 million (USD 93.6 million) | RMB 518.0 million |
| Administrative expense | RMB 139.4 million (USD 20.0 million) | RMB 122.4 million |
| Operating loss | RMB 805.6 million (USD 115.7 million) | RMB 631.4 million |
| Net loss | RMB 797.1 million (USD 114.4 million) | RMB 1,306.8 million |
| Net cash used in operating activities | RMB 679.7 million (USD 97.6 million) | RMB 544.9 million |
| Cash and cash equivalents | RMB 550.3 million (USD 79.0 million) | RMB 1,706.9 million |
At year-end, short-term investments were RMB 511.3 million (USD 73.4 million) and long-term investments were RMB 65.7 million (USD 9.4 million). Management said cash, cash equivalents and short-term investments were expected to fund anticipated operating needs for at least 12 months. The company had no debt outstanding; total liabilities were RMB 115.1 million, mainly trade payables and accruals, with lease liabilities of RMB 3.0 million. Gross margin is not applicable because the company had no product revenue.
Material changes versus the prior comparable period
- Net loss narrowed by RMB 509.8 million, but operating loss widened by RMB 174.2 million as R&D and administrative expenses increased. R&D expense rose primarily with later-stage clinical work.
- The lower net loss largely reflects the absence of the prior-year RMB 674.3 million fair-value loss on preferred financial instruments, which converted to ordinary shares in connection with the 2021 IPO. The improvement does not represent operating profitability.
- Operating cash use increased by RMB 134.7 million. The RMB 571.3 million investing cash outflow was primarily net purchases of financial investments, rather than operating expenditure; cash and cash equivalents fell by RMB 1,251.6 million during the year.
- The company recorded RMB 32.8 million (USD 4.7 million) of impairment losses after ending plans to build a Taicang laboratory, manufacturing facility and offices. It reported no capital commitments at year-end, compared with RMB 146.9 million at the end of 2021.
- Government grant income fell to RMB 6.4 million from RMB 19.0 million, partly because 2021 included a one-time RMB 11.0 million IPO-related grant.
Pipeline, outlook and risks
- CBP-201: The global Phase 2b atopic dermatitis trial met its primary and key secondary endpoints and was generally well tolerated. In the China pivotal trial’s 16-week Stage 1, 30.3% of patients on CBP-201 achieved the primary IGA response versus 7.5% on placebo; EASI-75 was 62.9% versus 23.4%. Stage 2 was ongoing. Management anticipated completion in the second half of 2023 and a China NDA submission in the first half of 2024. A global Phase 3 program was contingent on securing a partner or other financing; no assurance of a partnership was given.
- CBP-201 in asthma: The global Phase 2 trial was fully enrolled at 306 patients; the filing does not report trial results.
- CBP-307: In the 145-patient global Phase 2 ulcerative colitis trial, the primary clinical-response result was numerical but not statistically significant; a clinical-remission measure was statistically significant. The company was seeking to out-license the program. A separate Phase 2 Crohn’s disease trial in China ended early after COVID-related enrollment challenges.
- CBP-174: The Phase 1 study in 72 healthy adults was completed in 2022 and the candidate was reported as generally well tolerated. Further development plans were not specified clearly.
- Management expected continued losses and significant R&D spending. The company said existing resources would not fund all candidates through regulatory approval and that further financing, licensing or partnerships would be needed. Equity financing could dilute shareholders; the company had an effective shelf registration for up to USD 300 million, including an ATM program of up to USD 150 million, with no sales reported through the filing.
- Material risks include clinical-trial delays or failures, safety findings, reliance on CROs and contract manufacturers, and dependence on a partner to fund CBP-201 Phase 3. COVID-19 and the war in Ukraine disrupted enrollment or data collection at some trial sites. The company also faces PRC regulatory, data-transfer, foreign-exchange and cross-border funding risks. It reported that the PCAOB’s December 2022 change in inspection status reduced its immediate HFCAA identification risk, but future access could change.
- After year-end, in April 2023, a Taicang authority agreed to repurchase the land-use rights at their original purchase price; cancellation procedures and receipt of funds were still pending. The filing also describes the 2023 Silicon Valley Bank disruption: the company said most deposits had been moved and it did not then anticipate access problems.
Key investor verification points
- Confirm current cash and investment balances, investment maturities and liquidity runway against ongoing clinical spending and the company’s financing needs.
- Check whether the China CBP-201 trial completed Stage 2, whether an NDA was submitted, and whether a partner or financing was secured for global Phase 3.
- Review full CBP-307 trial data, particularly the nonsignificant primary endpoint, the remission result, safety findings and any licensing progress.
- Verify the timing and actual receipt of the Taicang land repurchase proceeds, and any related accounting or grant consequences.
- Monitor subsequent filings for financing, dilution, clinical updates, PRC regulatory or data-compliance developments, and any renewed PCAOB/HFCAA listing exposure.
Controls and contingencies: Management reported that two previously identified material weaknesses in financial reporting controls were remediated during 2022 and that controls were effective at year-end. The auditor did not provide an attestation on internal control. The company reported no material litigation and no dividends declared or paid in 2022.